EssilorLuxottica: S&P Upgrades Long-Term Credit Rating to A+, Stable Outlook
The rating agency's decision concerns the long-term credit rating of the group and is accompanied by a stable outlook, according to the press release published by EssilorLuxottica on October 23, 2026. S&P Global Ratings justifies this upgrade by the group's organic growth trajectory and financial position.
Organic Growth, Cash Flows and Balance Sheet Support the Decision
According to EssilorLuxottica's press release, S&P Global Ratings has upgraded the group's long-term credit rating to A+, with a stable outlook.
This upgrade reflects the agency's recognition of three elements: EssilorLuxottica's organic growth trajectory, the strength of its cash flows and the strength of its balance sheet.
Strategic Evolution Towards Eye Care and Medical Technologies
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The agency highlights, according to the press release, the group's strategic evolution: from a consumer-centric model to a positioning in eye care and medical technologies.
S&P Global Ratings presents this evolution as a key driver of EssilorLuxottica's future growth and financial resilience. Details of the analysis are contained in the press release published by S&P Global Ratings.
SectorDispositifs médicaux et optique›Optique / lunetterie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 22 304 millions d'euros
Quarterly revenue: 22 304 millions d'euros
Revenue growth: 6,8 %
Opportunities identified
Le portefeuille des solutions de gestion de la myopie a progressé de +24 % sur les neuf premiers mois
Les activités traditionnelles (Eyecare & Medtech) ont progressé à un rythme supérieur à +6 %, tant au T3 que sur les neuf premiers mois
Segment Direct to Consumer en hausse de +10,6 % au T3, ventes à magasins comparables à +6,8 %
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
